Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.
Educational information
This lecture by prof. Peter van der Meer was part of a CME accredited symposium "RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes" held during ERA-EDTA 2019 in Budapest, Hungary.
Faculty
Prof. van der Meer received both this MD and PhD cum laude from the University of Groningen in the Netherlands and worked as a visiting scientist at Harvard Medical School, Boston, MA, USA. He is a cardiologist and director of the coronary care unit at the UMCG, Groningen, The Netherlands. His research-group consists of PhD students and post-docs with various backgrounds working on (translational) research topics.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma.
Online-CME
This is available as accredited online CME for members. Click the button below to enroll:
Enroll
Share this page with your colleagues and friends: